Historical Valuation
Viridian Therapeutics Inc (VRDN) is now in the Fair zone, suggesting that its current forward PS ratio of 62.53 is considered Fairly compared with the five-year average of -4.77. The fair price of Viridian Therapeutics Inc (VRDN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：31.75
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Viridian Therapeutics Inc (VRDN) has a current Price-to-Book (P/B) ratio of 8.03. Compared to its 3-year average P/B ratio of 4.19 , the current P/B ratio is approximately 91.60% higher. Relative to its 5-year average P/B ratio of 4.28, the current P/B ratio is about 87.81% higher. Viridian Therapeutics Inc (VRDN) has a Forward Free Cash Flow (FCF) yield of approximately -11.14%. Compared to its 3-year average FCF yield of -16.74%, the current FCF yield is approximately -33.43% lower. Relative to its 5-year average FCF yield of -17.89% , the current FCF yield is about -37.70% lower.
P/B
Median3y
4.19
Median5y
4.28
FCF Yield
Median3y
-16.74
Median5y
-17.89
Competitors Valuation Multiple
AI Analysis for VRDN
The average P/S ratio for VRDN competitors is 34.09, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN.O) exhibits a P/S ratio of 62.53, which is 83.42% above the industry average. Given its robust revenue growth of 81958.14%, this premium appears sustainable.
Performance Decomposition
AI Analysis for VRDN
1Y
3Y
5Y
Market capitalization of VRDN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VRDN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VRDN currently overvalued or undervalued?
Viridian Therapeutics Inc (VRDN) is now in the Fair zone, suggesting that its current forward PS ratio of 62.53 is considered Fairly compared with the five-year average of -4.77. The fair price of Viridian Therapeutics Inc (VRDN) is between to according to relative valuation methord.
What is Viridian Therapeutics Inc (VRDN) fair value?
VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Viridian Therapeutics Inc (VRDN) is between to according to relative valuation methord.
How does VRDN's valuation metrics compare to the industry average?
The average P/S ratio for VRDN's competitors is 34.09, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 62.53, which is 83.42% above the industry average. Given its robust revenue growth of 81958.14%, this premium appears sustainable.
What is the current P/B ratio for Viridian Therapeutics Inc (VRDN) as of Jan 10 2026?
As of Jan 10 2026, Viridian Therapeutics Inc (VRDN) has a P/B ratio of 8.03. This indicates that the market values VRDN at 8.03 times its book value.
What is the current FCF Yield for Viridian Therapeutics Inc (VRDN) as of Jan 10 2026?
As of Jan 10 2026, Viridian Therapeutics Inc (VRDN) has a FCF Yield of -11.14%. This means that for every dollar of Viridian Therapeutics Inc’s market capitalization, the company generates -11.14 cents in free cash flow.
What is the current Forward P/E ratio for Viridian Therapeutics Inc (VRDN) as of Jan 10 2026?
As of Jan 10 2026, Viridian Therapeutics Inc (VRDN) has a Forward P/E ratio of -7.66. This means the market is willing to pay $-7.66 for every dollar of Viridian Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Viridian Therapeutics Inc (VRDN) as of Jan 10 2026?
As of Jan 10 2026, Viridian Therapeutics Inc (VRDN) has a Forward P/S ratio of 62.53. This means the market is valuing VRDN at $62.53 for every dollar of expected revenue over the next 12 months.